Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
August 04, 2021 16:05 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam
July 27, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
– First clinical trial to specifically study confirmed carbapenem-resistant Acinetobacter infections– – Phase 3 top-line data readout now anticipated in early 4Q 2021 – ...
Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer
July 14, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
– Significant commercial strategy and product launch experience –– ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 – WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis...
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens
July 01, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum
June 18, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 05, 2021 16:05 ET
|
Entasis Therapeutics Holdings Inc.
– ATTACK Phase 3 topline data readout remains on track for second half of 2021 – – Strengthened balance sheet with $20M financing – WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) --...
Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva
May 03, 2021 16:05 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
March 23, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
– Phase 3 ATTACK registration trial more than three-quarters complete –– ATTACK topline data readout expected second half of 2021 –– Zoliflodacin Phase 3 trial adds clinical trial sites, continues...
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.
January 26, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference
January 07, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...